New Analysis Challenges Decades-Old Breast Cancer Overdiagnosis Estimates
A new study is challenging long-standing concerns about the risks of breast cancer screening. Researchers conducted a systematic reanalysis of all eight major randomized mammography trials, carefully accounting for variables that earlier analyses may have overlooked—specifically differences in follow-up time, screening frequency, and whether participants continued screening after trials concluded.
The findings, published in a peer-reviewed journal, produced consistently lower overdiagnosis estimates than previous high-profile studies. Rather than the 30% to 50% overdiagnosis rates cited in some prior research, the new analysis points to rates below 5%.
Overdiagnosis in cancer screening refers to the detection of tumors that would never have caused symptoms or death during a patient's lifetime. These cases lead to unnecessary treatment and patient distress, making accurate estimates crucial for public health policy and individual decision-making.
The researchers note that methodological differences explain much of the gap between old and new estimates. Earlier studies may have conflated overdiagnosis with cases where screening simply moved forward the time of diagnosis—a phenomenon sometimes called "length-biased sampling," which is not true overdiagnosis.
While the analysis offers reassurance about the proportionality of benefits versus harms in population screening programs, experts emphasize that individual patient preferences and risk profiles should continue to guide screening decisions.